DIAGNOSTIC AND RESEARCH REAGENTS FOR HHV-8

HHV-8 的诊断和研究试剂

• 批准号: 6017570
• 负责人: MARY PAT MOYER
• 金额: $ 9.99万
• 依托单位: INCELL CORPORATION, LLC
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-09-30 至 2000-02-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6017570
• 关键词: Herpesviridae disease; Kaposi's sarcoma; antiviral antibody; cell line; clinical research; communicable disease diagnosis; diagnosis design /evaluation; diagnosis quality /standard; enzyme linked immunosorbent assay; genetic library; human herpesvirus 8; human subject; laboratory rabbit; monoclonal antibody; virus antigen

This project has the purpose of developing diagnostic and research reagents for assaying human herpes virus type 8 (HHV-8), the causative agent of the AIDS-associated malignancies, Kaposi s sarcoma and body cavity-based lymphoma. The proposal is being submitted on the Fast-Track, with Phase I having the following Specific Aims: [1] HHV-8-specific rabbit polyclonal antibody will be characterized for potential research and diagnostic applications; [2] The construction of an expression cDNA library for the identification of proteins recognized by the anti-HHV8 antibody; and [3] ORF65-specific monoclonal antibodies will be cloned, characterized, expanded in vitro and comparatively evaluated for potential commercialization. The work will validate preliminary studies showing the utility of the antibody and viral reagents which have already been developed as proof-of- concept that they can be further developed into commercial products during the Phase II work. The deliverable outcomes of the overall project will be diagnostic test kits for suspected HHV-8 patients, and blood and tissue donors, as well as reagents for research studies of HHV-8 replication. PROPOSED COMMERCIAL APPLICATION Diagnostic ELISA test kits will be developed for testing patients potentially infected with HHV-8 or to test blood and tissue donors. Antibodies and other research reagents will be developed as tools to study HHV-8 replication.

该项目的目的是开发用于分析人类疱疹病毒8型（HHV-8）的诊断和研究试剂，这是艾滋病相关恶性肿瘤的致病药物，卡波西肉瘤和基于人体腔体淋巴瘤。 该提案正在快速轨道上提交，I阶段具有以下特定目的：[1] HHV-8特异性兔多克隆抗体的特征是潜在的研究和诊断应用； [2]构建表达cDNA文库，以鉴定抗HHV8抗体识别的蛋白质； [3] ORF65特异性单克隆抗体将被克隆，表征，体外扩展，并相对评估以进行潜在的商业化。 这项工作将验证初步研究表明抗体和病毒试剂的实用性已经被开发为概念证明，在II期工作期间它们可以进一步发展为商业产品。 整个项目的可交付结果将是可疑HHV-8患者以及血液和组织供体的诊断测试套件，以及用于HHV-8复制研究的试剂。提出的商业应用诊断ELISA测试套件将用于测试潜在感染HHV-8或测试血液和组织供体的患者。 将开发抗体和其他研究试剂作为研究HHV-8复制的工具。